{
  "id": 10137141,
  "title": "Core Scientific chief legal officer Todd Duchene sells $183,746 in shares",
  "url": "https://urgent.news/2026/09/27/core-scientific-chief-legal-officer-todd-duchene-sells-183-746-in",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-27T04:31:36.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/core-scientific-chief-legal-officer-todd-duchene-sells-183746-in-shares-93CH-4918801"
  },
  "original_language": "en",
  "account": "Core Scientific, a publicly traded company, recently reported notable financial activity and strategic partnerships that have impacted its stock performance. On September 21, 2026, Todd M. Duchene, the company's Chief Legal and Administrative Officer, sold 10,000 shares of Core Scientific common stock, totaling $183,746. This sale, conducted in accordance with a pre-approved Rule 10b5-1 trading plan, was executed at prices between $17.81 and $18.64 per share, below the current market price of $17.34. Duchene's total stake in the company now stands at 1,197,896 shares, with an indirect ownership of 700,000 shares through a grantor retained annuity trust.\n\nAnalysts have mixed views on Core Scientific's current valuation, with some identifying it as overvalued. However, the company has recently secured strategic partnerships that are expected to positively influence its market position. Core Scientific recently announced a partnership with AMD, which is expected to add 530 megawatts to the company's existing 590 megawatts of leased power. This move has led to an upgrade in the stock rating from \"Hold\" to \"Buy\" by Freedom Broker, with a price target of $33.00. Similar upgrades were made by Compass Point and Canaccord, who set their price targets at $36.00, citing the AMD deal and increased revenue as key drivers. Additionally, UBS initiated coverage with a \"Buy\" rating and a target price of $24.00, anticipating the delivery of AMD-backed capacity to enhance investor confidence. Despite these positive developments, Rothschild Redburn maintains a \"Neutral\" rating with a price target of $16.00. These developments signal a significant shift in market perception of Core Scientific as it navigates the evolving landscape of data center infrastructure.",
  "summary": null,
  "key_points": [
    "Todd Duchene sold 10,000 shares of Core Scientific for $183,746",
    "Strategic partnership with AMD expected to add 530 megawatts",
    "Analysts upgraded Core Scientific stock rating to Buy"
  ],
  "editors_take": "The sale of shares by Core Scientific's chief legal officer suggests insiders may be taking a cautious view despite recent upgrades and partnerships boosting the company's market position and outlook.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}